Steven A. Narod

Active 1991–2025

Also published as
Steven A Narod
331
Papers
80,725
Citations
138
h-index
326
i10-index

Citations

Citations per year for Steven A. Narod1882: 1 citations1988: 1 citations1991: 2 citations1993: 8 citations1994: 11 citations1995: 106 citations1996: 195 citations1997: 315 citations1998: 262 citations1999: 264 citations2000: 364 citations2001: 354 citations2002: 441 citations2003: 379 citations2004: 461 citations2005: 567 citations2006: 554 citations2007: 560 citations2008: 605 citations2009: 626 citations2010: 809 citations2011: 640 citations2012: 604 citations2013: 545 citations2014: 647 citations2015: 593 citations2016: 664 citations2017: 570 citations2018: 514 citations2019: 1,829 citations2020: 1,908 citations2021: 1,585 citations2022: 1,200 citations2023: 734 citations2024: 1,309 citations2025: 493 citations2026: 12 citations1883–1987: no citations, so these years are not shown1989–1990: no citations, so these years are not shown1992: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 6,127 citing papers, 26.9% of this breakdownUnited Kingdom: 1,753 citing papers, 7.7% of this breakdownChina: 1,684 citing papers, 7.4% of this breakdownCanada: 1,327 citing papers, 5.8% of this breakdownItaly: 941 citing papers, 4.1% of this breakdownGermany: 894 citing papers, 3.9% of this breakdownAustralia: 811 citing papers, 3.6% of this breakdownNetherlands: 751 citing papers, 3.3% of this breakdownFrance: 721 citing papers, 3.2% of this breakdownSpain: 546 citing papers, 2.4% of this breakdownSweden: 461 citing papers, 2% of this breakdownJapan: 414 citing papers, 1.8% of this breakdown
0%26.9%Other 27.9%

Fields

  • Biochemistry, Genetics and Molecular Biology50.6%
  • Medicine42.7%
  • Immunology and Microbiology1.4%
  • Computer Science1.1%
  • Engineering0.7%
  • Materials Science0.6%
  • Other2.9%

Topics

  • BRCA gene mutations in cancer9.6%
  • Breast Cancer Treatment Studies4.5%
  • Ovarian cancer diagnosis and treatment3.7%
  • DNA Repair Mechanisms3.5%
  • Cancer Genomics and Diagnostics3.3%
  • PARP inhibition in cancer therapy3%
  • Other72.4%

Coauthors

All papers

Open in search
  1. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

    Authors: , , , , , , , , , - Clinical Cancer Research 2007 cited by 5,106

  2. CA125 and Ovarian Cancer: A Comprehensive Review

    Authors: , , , , , - Cancers 2020 cited by 622

  3. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Steven A. Narod, Brad H. Nelson, Kenneth P. Nephew, Paul D.P. Pharoah, Daniel J. Powell, Pilar Ramos, Iris L. Romero, Clare L. Scott, Anil K. Sood, Euan A. Stronach, Frances R. Balkwill - Nature reviews. Cancer 2015 cited by 1,425

  4. A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Steven A. Narod, Pam K. Bristow, Frank H. Norris, Leah M. Helvering, P. Morrison, Paul R. Rosteck, Mei Lai, J. Carl Barrett, Cathryn M. Lewis, Susan L. Neuhausen, Lisa Cannon‐Albright, David E. Goldgar, Roger W. Wiseman, Alexander Kamb, Mark H. Skolnick - Science 1994 cited by 6,116

  5. Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fiona Lalloo, D. Gareth Evans, Douglas F. Easton - The American Journal of Human Genetics 2003 cited by 3,685

  6. Identification of the breast cancer susceptibility gene BRCA2

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Cees J. Cornelisse, Henry T. Lynch, Steven A. Narod, Gilbert Lenoir, V Egilsson, Rosa Bjork Barkadottir, Douglas F. Easton, David Bentley, P. Andrew Futreal, Alan Ashworth, Michael R. Stratton - Nature 1995 cited by 3,663

  7. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Karim Fizazi, Virginie Galibert, Laurence Gladieff, Joseph Gligorov, Pascal Hammel, Marion Imbert‐Bouteille, William Jacot, Tatiana Kogut-Kubiak, Pierre‐Jean Lamy, Sophie Nambot, Y. Neuzillet, Sylviane Olschwang, Xavier Rébillard, Jean‐Marc Rey, Chloé Rideau, Jean-Philippe Spano, Frédéric Thomas, Isabelle Treilleux, Marion Vandromme, Julie A. Vendrell, Michèle Vintraud, D. Zarca, Kevin S. Hughes, Jose Enrique Alés Martínez - European Journal of Cancer 2021 cited by 175

  8. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ

    Authors: , , , , - JAMA Oncology 2015 cited by 622

  9. Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group

    Authors: , , , , , , , , , , , , - Journal of Clinical Oncology 2004 cited by 1,146

  10. Differences in Breast Cancer Stage at Diagnosis and Cancer-Specific Survival by Race and Ethnicity in the United States

    Authors: , , , , - JAMA 2015 cited by 615

  11. BRCA1 and BRCA2: 1994 and beyond

    Authors: , - Nature reviews. Cancer 2004 cited by 968

  12. Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2014 cited by 655

  13. Localization of a Breast Cancer Susceptibility Gene, BRCA2 , to Chromosome 13q12-13

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael R. Stratton - Science 1994 cited by 1,900

  14. Pattern of metastatic spread in triple-negative breast cancer

    Authors: , , , , , - Breast Cancer Research and Treatment 2008 cited by 558

  15. Analysis of Platelet Count and New Cancer Diagnosis Over a 10-Year Period

    Authors: , , , , , , , , - JAMA Network Open 2022 cited by 111

  16. Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , N E Haites, Rodney J. Scott, C.M. Maugard, Hans F. A. Vasen, Susanne Seitz, Lisa Cannon‐Albright, Andrew Craig Schofield, M Zelada-Hedman - The American Journal of Human Genetics 1998 cited by 3,047

  17. Can advanced-stage ovarian cancer be cured?

    Authors: - Nature Reviews Clinical Oncology 2016 cited by 401

  18. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Victoria Murday, Catherine Phelan, Steven A. Narod, T. Peretz, Julian Peto, Julian Peto, Barbara L. Weber, Hong Xiang Zhang, Katherine L. Nathanson, David E. Goldgar, Csilla I. Szabo - Nature Genetics 2002 cited by 1,109

  19. Breast cancer in young women

    Authors: - Nature Reviews Clinical Oncology 2012 cited by 249

  20. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Douglas F. Easton - British Journal of Cancer 2008 cited by 535

  21. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation

    Authors: , , , , , , , , , , , , , , , , , - British Journal of Cancer 2019 cited by 179

  22. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma

    Authors: , , , , , , , , , , - Journal of Clinical Oncology 2015 cited by 396

  23. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis

    Authors: , , , , , , , , - BMJ 2016 cited by 274

  24. Blood Copper Levels and the Occurrence of Colorectal Cancer in Poland

    Authors: , , , , , , , , , , , , , , - Biomedicines 2021 cited by 48